|
Symposium
Immuno-Oncology: Advances in Translating from Bench to Clinic
Speakers:
Luis Borges, Deborah Charych, Ravi Majeti, Brian Wong, Juan Jaen, Tara Arvedson, Jason DeVoss, Lelia Delamarre, Cheng Liu
Organizers:
Snow Ge (Nektar), Deborah Charych (Nektar), Wenfeng Xu (Genentech)
Date:
2017-06-28
Time:
8:45-17:00 Pacific Time
Registration fee:
(USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location:
Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date:
(23)Applied BioMath; Aragen Bioscience, Inc.; BioLegend; Bio-Techne; Cardinal Health; Cellular Dynamics Intl; Covance; CrownBio; Cytovier LLC; Eurofins; Eurofins Discovery; Fujifilm Diosynth Biotechnologies; Intertek; PeproTech Inc; PharmaLegacy; PHARMout Laboratories; PPD; Premier Research; Quintara Discovery (QDI); Science Exchange; Second Genome; ThermoFisher; WuXi Apptec
Registration: http://www.PBSS.org
Registration deadline:2017-06-27
(it will close sooner if the seating cap is reached)
About the Topic
8:45-8:55 Opening Remarks and Introduction
8:55-9:35 Discovery of new drug targets and therapeutic approaches for cancer immunotherapy (Luis Borges, SVP, Five Prime Therapeutics)
9:35-10:15 Harnessing the Potent IL2 Immune Stimulatory Pathway with Designer Polymers (Deborah Charych, ED, Nektar)
10:15-10:25 Major sponsor presentation (Charles River)
10:25-10:40 Break
10:40-11:20 Pre-Clinical Development of a Humanized Anti-CD47 Antibody (Ravi Majeti, Professor, Stanford)
11:20-12:00 Discovery and development of orally-available cancer immunotherapies (Brian Wong, CEO, FLX Bio)
12:00-1:00 Lunch
1:00-1:40 Small Molecules, Antibodies, and Cell-based Therapies in the Fight Against Cancer (Juan Jaen, Founder and President, Arcus Biosciences and PACT Pharma)
1:40-2:20 Blincyto and BiTE® Antibody Platform for Cancer Therapy (Tara Arvedson, Principal Scientist, Amgen)
2:20-2:30 Major sponsor presentation (Celerion)
2:30-2:45 Break
2:45-3:25 T-VEC and oncolytic therapy (Jason DeVoss, Sr. Scientist, Amgen)
3:25-4:05 Personalized Cancer Vaccine (Lelia Delamarre, Sr. Scientist, Genentech)
4:05-4:15 Break
4:15-4:55 After CD19: CAR-T for solid tumor (Cheng Liu, CEO, Eureka)
4:55-5:15 General Q&A
2023-12-06, [Free Online] Artificial Intelligence and Machine Learning to Drive Therapeutic Drug Discovery & Development
|
2024-01-19, [In-Person] ADME/DMPK Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-02-06, [In-Person] Antibody Discovery and Development: Hit Generation, Engineering, Characterization, CMC and IND Enabling studies
|
2024-03-07, [In-Person] Project Management for Drug Development
|
2024-03-28, [In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Viva Biotech
Join Viva Reception if you have a need in MedChem, SBDD, FBDD, CryoEM, ASMS, SPR, HDX, CADD, Bioassay, CMC, Ab, https://www.bagevent.com/event/8673557
|
Alturas Analytics, Inc.
Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
|
BioTether Sciences
Bioanalytical CRO, focused on PK, Biomarkers, and Immunogenicity. Custom Assay development, validation and testing. Advanced cell engineering.
|
Allucent
Bringing innovation to Biopharma, w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
ICON
Innovation Workshop in SF Bay Area: Bringing the trial to the patient: Are you driving true patient centricity? Oct 19, Crowne Plaza Foster
|
Submit a Text Ad
|